KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBIT (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBIT for 15 consecutive years, with -$32.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 46.61% year-over-year to -$32.4 million, compared with a TTM value of -$62.8 million through Dec 2025, up 80.6%, and an annual FY2025 reading of -$62.8 million, up 80.6% over the prior year.
  • EBIT was -$32.4 million for Q4 2025 at Travere Therapeutics, down from $24.9 million in the prior quarter.
  • Across five years, EBIT topped out at $24.9 million in Q3 2025 and bottomed at -$139.2 million in Q1 2024.
  • Average EBIT over 5 years is -$66.4 million, with a median of -$69.8 million recorded in 2022.
  • The sharpest move saw EBIT tumbled 215.58% in 2021, then skyrocketed 144.4% in 2025.
  • Year by year, EBIT stood at -$84.8 million in 2021, then crashed by 41.54% to -$120.1 million in 2022, then increased by 21.54% to -$94.2 million in 2023, then surged by 35.55% to -$60.7 million in 2024, then surged by 46.61% to -$32.4 million in 2025.
  • Business Quant data shows EBIT for TVTX at -$32.4 million in Q4 2025, $24.9 million in Q3 2025, and -$12.6 million in Q2 2025.